TELA Bio (TELA) EBIAT (2018 - 2025)
TELA Bio has reported EBIAT over the past 8 years, most recently at -$9.0 million for Q4 2025.
- Quarterly results put EBIAT at -$9.0 million for Q4 2025, up 1.81% from a year ago — trailing twelve months through Dec 2025 was -$38.8 million (down 2.62% YoY), and the annual figure for FY2025 was -$38.8 million, down 2.62%.
- EBIAT for Q4 2025 was -$9.0 million at TELA Bio, down from -$8.6 million in the prior quarter.
- Over the last five years, EBIAT for TELA hit a ceiling of -$5.7 million in Q1 2024 and a floor of -$12.9 million in Q4 2023.
- Median EBIAT over the past 5 years was -$10.2 million (2022), compared with a mean of -$10.0 million.
- Biggest five-year swings in EBIAT: surged 52.93% in 2024 and later plummeted 98.98% in 2025.
- TELA Bio's EBIAT stood at -$8.6 million in 2021, then decreased by 15.78% to -$10.0 million in 2022, then dropped by 29.17% to -$12.9 million in 2023, then grew by 28.56% to -$9.2 million in 2024, then grew by 1.81% to -$9.0 million in 2025.
- The last three reported values for EBIAT were -$9.0 million (Q4 2025), -$8.6 million (Q3 2025), and -$9.9 million (Q2 2025) per Business Quant data.